Familial hyperaldosteronism type III

[1]  H. Sasano,et al.  Disordered zonal and cellular CYP11B2 enzyme expression in familial hyperaldosteronism type 3 , 2017, Molecular and Cellular Endocrinology.

[2]  D. Hoffman,et al.  Functional characterization of two novel germline mutations of the KCNJ5 gene in hypertensive patients without primary aldosteronism but with ACTH‐dependent aldosterone hypersecretion , 2016, Clinical endocrinology.

[3]  Jiong Cai,et al.  A Novel Phenotype of Familial Hyperaldosteronism Type III: Concurrence of Aldosteronism and Cushing's Syndrome. , 2016, The Journal of clinical endocrinology and metabolism.

[4]  J. Lenders,et al.  Study Heterogeneity and Estimation of Prevalence of Primary Aldosteronism: A Systematic Review and Meta-Regression Analysis. , 2016, The Journal of clinical endocrinology and metabolism.

[5]  W. Young,et al.  The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. , 2016, The Journal of clinical endocrinology and metabolism.

[6]  U. Scholl,et al.  An Update on Familial Hyperaldosteronism , 2015, Hormone and Metabolic Research.

[7]  P. Mulatero,et al.  Understanding primary aldosteronism: impact of next generation sequencing and expression profiling , 2015, Molecular and Cellular Endocrinology.

[8]  K. Muroya,et al.  Discordant Genotype-Phenotype Correlation in Familial Hyperaldosteronism Type III with KCNJ5 Gene Mutation: A Patient Report and Review of the Literature , 2014, Hormone Research in Paediatrics.

[9]  M. Stowasser,et al.  Role for Germline Mutations and a Rare Coding Single Nucleotide Polymorphism Within the KCNJ5 Potassium Channel in a Large Cohort of Sporadic Cases of Primary Aldosteronism , 2014, Hypertension.

[10]  F. Beuschlein,et al.  Pharmacology and pathophysiology of mutated KCNJ5 found in adrenal aldosterone-producing adenomas. , 2014, Endocrinology.

[11]  F. Veglio,et al.  Long-term cardio- and cerebrovascular events in patients with primary aldosteronism. , 2013, The Journal of clinical endocrinology and metabolism.

[12]  P. Mulatero,et al.  a Novel Y152C KCNJ5 mutation responsible for familial hyperaldosteronism type III. , 2013, The Journal of clinical endocrinology and metabolism.

[13]  P. Plouin,et al.  Cardiovascular Complications Associated With Primary Aldosteronism: A Controlled Cross-Sectional Study , 2013, Hypertension.

[14]  Annabelle L. Fonseca,et al.  Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism , 2013, Nature Genetics.

[15]  F. Veglio,et al.  Role of KCNJ5 in familial and sporadic primary aldosteronism , 2013, Nature Reviews Endocrinology.

[16]  C. Gomez-Sanchez,et al.  The potassium channel, Kir3.4 participates in angiotensin II-stimulated aldosterone production by a human adrenocortical cell line. , 2012, Endocrinology.

[17]  R. Camilla,et al.  Polyuric-polydipsic syndrome in a pediatric case of non-glucocorticoid remediable familial hyperaldosteronism. , 2012, Endocrine journal.

[18]  D. Hoffman,et al.  A novel point mutation in the KCNJ5 gene causing primary hyperaldosteronism and early-onset autosomal dominant hypertension. , 2012, The Journal of clinical endocrinology and metabolism.

[19]  R. Bollag,et al.  Effect of KCNJ5 mutations on gene expression in aldosterone-producing adenomas and adrenocortical cells. , 2012, The Journal of clinical endocrinology and metabolism.

[20]  Morris J. Brown,et al.  Microarray, qPCR, and KCNJ5 sequencing of aldosterone-producing adenomas reveal differences in genotype and phenotype between zona glomerulosa- and zona fasciculata-like tumors. , 2012, The Journal of clinical endocrinology and metabolism.

[21]  C. Gomez-Sanchez,et al.  Potassium channel mutant KCNJ5 T158A expression in HAC-15 cells increases aldosterone synthesis. , 2012, Endocrinology.

[22]  T. Strom,et al.  KCNJ5 Mutations in European Families With Nonglucocorticoid Remediable Familial Hyperaldosteronism , 2012, Hypertension.

[23]  R. Lifton,et al.  Hypertension with or without adrenal hyperplasia due to different inherited mutations in the potassium channel KCNJ5 , 2012, Proceedings of the National Academy of Sciences.

[24]  C. Gomez-Sanchez,et al.  18-hydroxycorticosterone, 18-hydroxycortisol, and 18-oxocortisol in the diagnosis of primary aldosteronism and its subtypes. , 2012, The Journal of clinical endocrinology and metabolism.

[25]  F. Veglio,et al.  Prevalence and Characteristics of Familial Hyperaldosteronism: The PATOGEN Study (Primary Aldosteronism in TOrino-GENetic forms) , 2011, Hypertension.

[26]  F. Veglio,et al.  Is familial hyperaldosteronism underdiagnosed in hypertensive children? , 2011, Hypertension.

[27]  M. Stowasser,et al.  Familial or genetic primary aldosteronism and Gordon syndrome. , 2011, Endocrinology and metabolism clinics of North America.

[28]  V. Mericq,et al.  Frequency of Familial Hyperaldosteronism Type 1 in a Hypertensive Pediatric Population: Clinical and Biochemical Presentation , 2011, Hypertension.

[29]  S. Mane,et al.  K+ Channel Mutations in Adrenal Aldosterone-Producing Adenomas and Hereditary Hypertension , 2011, Science.

[30]  P. Ellinor,et al.  Identification of a Kir3.4 mutation in congenital long QT syndrome. , 2010, American journal of human genetics.

[31]  F. Veglio,et al.  Differential diagnosis of primary aldosteronism subtypes , 2009, Current hypertension reports.

[32]  W. Young,et al.  Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. , 2008, The Journal of clinical endocrinology and metabolism.

[33]  R. Lifton,et al.  A novel form of human mendelian hypertension featuring nonglucocorticoid-remediable aldosteronism. , 2008, The Journal of clinical endocrinology and metabolism.

[34]  D. Duffy,et al.  Further evidence for linkage of familial hyperaldosteronism type II at chromosome 7p22 in Italian as well as Australian and South American families , 2008, Journal of hypertension.

[35]  P. Mulatero.  A new form of hereditary primary aldosteronism: familial hyperaldosteronism type III. , 2008, The Journal of clinical endocrinology and metabolism.

[36]  L. Pott,et al.  Generation of a constitutive Na+‐dependent inward‐rectifier current in rat adult atrial myocytes by overexpression of Kir3.4 , 2007, The Journal of physiology.

[37]  J. Sharman,et al.  Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I. , 2005, The Journal of clinical endocrinology and metabolism.

[38]  P. Milliez,et al.  Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. , 2005, Journal of the American College of Cardiology.

[39]  E. Trabetti,et al.  Glucocorticoid remediable aldosteronism (GRA) screening in hypertensive patients from a primary care setting , 2005, Journal of Human Hypertension.

[40]  Ming Lei,et al.  Specific pattern of ionic channel gene expression associated with pacemaker activity in the mouse heart , 2005, The Journal of physiology.

[41]  F. Veglio,et al.  Genetics of primary aldosteronism , 2004, Journal of hypertension.

[42]  M. Stowasser,et al.  Primary aldosteronism—careful investigation is essential and rewarding , 2004, Molecular and Cellular Endocrinology.

[43]  W. Young,et al.  Increased Diagnosis of Primary Aldosteronism, Including Surgically Correctable Forms, in Centers from Five Continents , 2004 .

[44]  M. Stowasser,et al.  High rate of detection of primary aldosteronism, including surgically treatable forms, after ‘non-selective’ screening of hypertensive patients , 2003, Journal of hypertension.

[45]  T. Zelinka,et al.  Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region , 2003, Journal of Human Hypertension.

[46]  C. Gomez-Sanchez,et al.  A time-resolved fluoroimmunoassay for 18-oxocortisol and 18-hydroxycortisol Development of a monoclonal antibody to 18-oxocortisol , 2002, The Journal of Steroid Biochemistry and Molecular Biology.

[47]  F. Veglio,et al.  Blood pressure in patients with primary aldosteronism is influenced by bradykinin B(2) receptor and alpha-adducin gene polymorphisms. , 2002, The Journal of clinical endocrinology and metabolism.

[48]  C. Gomez-Sanchez,et al.  Glucocorticoid remediable aldosteronism: low morbidity and mortality in a four-generation italian pedigree. , 2002, The Journal of clinical endocrinology and metabolism.

[49]  S. Portrat,et al.  Deletion hybrid genes, due to unequal crossing over between CYP11B1 (11beta-hydroxylase) and CYP11B2(aldosterone synthase) cause steroid 11beta-hydroxylase deficiency and congenital adrenal hyperplasia. , 2001, The Journal of clinical endocrinology and metabolism.

[50]  D. Clapham,et al.  Evaluation of the role of I(KACh) in atrial fibrillation using a mouse knockout model. , 2001, Journal of the American College of Cardiology.

[51]  R. Lifton,et al.  Glucocorticoid-remediable aldosteronism is associated with severe hypertension in early childhood. , 2001, The Journal of pediatrics.

[52]  N. Haites,et al.  Is random screening of value in detecting glucocorticoid-remediable aldosteronism within a hypertensive population? , 2001, Journal of Human Hypertension.

[53]  Carissa M Krane,et al.  Early polyuria and urinary concentrating defect in potassium deprivation. , 2000, American journal of physiology. Renal physiology.

[54]  A. Bachmann,et al.  Treatment of familial hyperaldosteronism type I: only partial suppression of adrenocorticotropin required to correct hypertension. , 2000, The Journal of clinical endocrinology and metabolism.

[55]  A. Bachmann,et al.  Severity of hypertension in familial hyperaldosteronism type I: relationship to gender and degree of biochemical disturbance. , 2000, The Journal of clinical endocrinology and metabolism.

[56]  C. Gomez-Sanchez,et al.  Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. , 2000, The Journal of clinical endocrinology and metabolism.

[57]  R. Lifton,et al.  Glucocorticoid-remediable aldosteronism and pregnancy. , 2000, Hypertension.

[58]  M. Boscaro,et al.  Mutations in CYP11B1 gene converting 11beta-hydroxylase into an aldosterone-producing enzyme are not present in aldosterone-producing adenomas. , 1999, The Journal of clinical endocrinology and metabolism.

[59]  X. Jeunemaître,et al.  Recombinant CYP11B genes encode enzymes that can catalyze conversion of 11-deoxycortisol to cortisol, 18-hydroxycortisol, and 18-oxocortisol. , 1998, The Journal of clinical endocrinology and metabolism.

[60]  D. Clapham,et al.  Identification of Native Atrial G-protein-regulated Inwardly Rectifying K+ (GIRK4) Channel Homomultimers* , 1998, The Journal of Biological Chemistry.

[61]  X. Jeunemaître,et al.  Structural analysis and evaluation of the aldosterone synthase gene in hypertension. , 1998, Hypertension.

[62]  M. Boscaro,et al.  Diagnosis of glucocorticoid-remediable aldosteronism in primary aldosteronism: aldosterone response to dexamethasone and long polymerase chain reaction for chimeric gene. , 1998, The Journal of clinical endocrinology and metabolism.

[63]  C. Stratakis,et al.  Human CYP11B2 (aldosterone synthase) maps to chromosome 8q24.3. , 1998, The Journal of clinical endocrinology and metabolism.

[64]  D. Clapham,et al.  Abnormal Heart Rate Regulation in GIRK4 Knockout Mice , 1998, Neuron.

[65]  R. Lifton,et al.  Evaluation of the dexamethasone suppression test for the diagnosis of glucocorticoid-remediable aldosteronism. , 1997, The Journal of clinical endocrinology and metabolism.

[66]  C. Gomez-Sanchez,et al.  Aldosterone-producing adenomas do not contain glucocorticoid-remediable aldosteronism chimeric gene duplications. , 1996, The Journal of clinical endocrinology and metabolism.

[67]  M. Tusié-Luna,et al.  Gene conversions and unequal crossovers between CYP21 (steroid 21-hydroxylase gene) and CYP21P involve different mechanisms. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[68]  X. Jeunemaître,et al.  Glucocorticoid-suppressible hyperaldosteronism and adrenal tumors occurring in a single French pedigree. , 1995, The Journal of clinical investigation.

[69]  J. Connell,et al.  Glucocorticoid-suppressible hyperaldosteronism: effects of crossover site and parental origin of chimaeric gene on phenotypic expression. , 1995, Clinical science.

[70]  M. Stowasser,et al.  A new genetic test for familial hyperaldosteronism type I aids in the detection of curable hypertension. , 1995, Biochemical and biophysical research communications.

[71]  K. Curnow,et al.  Genetic recombination as a cause of inherited disorders of aldosterone and cortisol biosynthesis and a contributor to genetic variation in blood pressure , 1995, Steroids.

[72]  R. Lifton,et al.  Glucocorticoid-remediable aldosteronism (GRA): Diagnosis, variability of phenotype and regulation of potassium homeostasis , 1995, Steroids.

[73]  J. Lalouel,et al.  Hereditary hypertension caused by chimaeric gene duplications and ectopic expression of aldosterone synthase , 1992, Nature genetics.

[74]  J. Connell,et al.  Glucocorticoid-suppressible hyperaldosteronism results from hybrid genes created by unequal crossovers between CYP11B1 and CYP11B2. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[75]  R. Lifton,et al.  Glucocorticoid-remediable aldosteronism in a large kindred: clinical spectrum and diagnosis using a characteristic biochemical phenotype. , 1992, Annals of internal medicine.

[76]  T. Kawamoto,et al.  Role of steroid 11 beta-hydroxylase and steroid 18-hydroxylase in the biosynthesis of glucocorticoids and mineralocorticoids in humans. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[77]  J. Lalouel,et al.  A chimaeric llβ-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension , 1992, Nature.

[78]  M. Tusié-Luna,et al.  The product of the CYP11B2 gene is required for aldosterone biosynthesis in the human adrenal cortex. , 1991, Molecular endocrinology.

[79]  M. Stowasser,et al.  CLINICAL AND PATHOLOGICAL DIVERSITY OF PRIMARY ALDOSTERONISM, INCLUDING A NEW FAMILIAL VARIETY , 1991, Clinical and experimental pharmacology & physiology.

[80]  M. New,et al.  Defective fasciculata zone function as the mechanism of glucocorticoid-remediable aldosteronism. , 1990, The Journal of clinical endocrinology and metabolism.

[81]  C. Gomez-Sanchez,et al.  Glucocorticoid-suppressible aldosteronism: a disorder of the adrenal transitional zone. , 1988, The Journal of clinical endocrinology and metabolism.

[82]  J. Connell,et al.  Dexamethasone-suppressible hyperaldosteronism. Adrenal transition cell hyperplasia? , 1986, Hypertension.

[83]  N. Fineberg,et al.  Adrenal steroid responses to ACTH in glucocorticoid-suppressible aldosteronism. , 1984, Hypertension.

[84]  J. Melby,et al.  Familial hyperaldosteronism, not suppressed by dexamethasone. , 1982, The Journal of clinical endocrinology and metabolism.

[85]  M. Weinberger,et al.  Anomalous postural aldosterone response in glucocorticoid-suppressible hyperaldosteronism. , 1981, The New England journal of medicine.

[86]  R. E. Peterson,et al.  Evidence for an unidentified ACTH-induced steroid hormone causing hypertension. , 1976, The Journal of clinical endocrinology and metabolism.

[87]  R. E. Peterson,et al.  Dexamethasone-suppressible hyperaldosteronism. , 1973, The Journal of clinical endocrinology and metabolism.

[88]  K. Yoshinaga,et al.  A case of glucocorticoid-responsive hyperaldosteronism. , 1968, The Journal of clinical endocrinology and metabolism.

[89]  R. E. Peterson,et al.  A New Form of Congenital Adrenal Hyperplasia1 , 1967 .

[90]  D. Sutherland,et al.  Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone. , 1966, Canadian Medical Association journal.

[91]  P. Howard,et al.  Primary aldosteronism due to adrenal hyperplasia; occurrence in a boy aged 10 years. , 1959, A.M.A. journal of diseases of children.

[92]  F. Bartter,et al.  Primary aldosteronism: clinical staff conference at the National Institutes of Health. , 1958, Annals of internal medicine.

[93]  C. Stratakis,et al.  A case of severe hyperaldosteronism caused by a de novo mutation affecting a critical salt bridge Kir3.4 residue. , 2015, The Journal of clinical endocrinology and metabolism.

[94]  张炜,et al.  Primary Aldosteronism , 2014, Springer New York.

[95]  F. Veglio,et al.  Mineralocorticoid receptor blockade in the protection of target organ damage. , 2006, Cardiovascular & hematological agents in medicinal chemistry.

[96]  N. Sonino,et al.  Coexistence of different phenotypes in a family with glucocorticoid-remediable aldosteronism , 2004, Journal of Human Hypertension.

[97]  R. Lifton,et al.  Intracranial aneurysm and hemorrhagic stroke in glucocorticoid-remediable aldosteronism. , 1998, Hypertension.

[98]  P. Corvol,et al.  The amino acid substitutions Ser288Gly and Val320Ala convert the cortisol producing enzyme, CYP11B1, into an aldosterone producing enzyme , 1997, Nature Structural Biology.